カテゴリー： QYResearch, 世界, 医療/バイオ

世界のムーコル症治療薬市場インサイト及び予測（注射、経口）

◆英語タイトル：Global Mucormycosis Treatment Drugs Market Insights, Forecast to 2028
	◆商品コード：QY22JLX10420 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：113 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥735,000	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,102,500	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,470,000	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、ムーコル症治療薬のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にムーコル症治療薬の世界市場のxxx％を占める「注射」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
ムーコル症治療薬の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのムーコル症治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

ムーコル症治療薬のグローバル主要企業には、Abbott Laboratories、Biocon、Cadila Pharmaceuticals、Novartis、F. Hoffman La Roche、Merck Sharp and Dohme、Mylan Labs、Bristol Myers Squibb、Bayer、Lonza Group、Sanofi、Johnson and Johnson、Pfizer、Gilead Sciencesなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

ムーコル症治療薬市場は、種類と用途によって区分されます。世界のムーコル症治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
注射、経口

【用途別セグメント】
病院、診療所、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- ムーコル症治療薬製品概要
- 種類別市場（注射、経口）
- 用途別市場（病院、診療所、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界のムーコル症治療薬販売量予測2017-2028
- 世界のムーコル症治療薬売上予測2017-2028
- ムーコル症治療薬の地域別販売量
- ムーコル症治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別ムーコル症治療薬販売量
- 主要メーカー別ムーコル症治療薬売上
- 主要メーカー別ムーコル症治療薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（注射、経口）
- ムーコル症治療薬の種類別販売量
- ムーコル症治療薬の種類別売上
- ムーコル症治療薬の種類別価格
・用途別市場規模（病院、診療所、その他）
- ムーコル症治療薬の用途別販売量
- ムーコル症治療薬の用途別売上
- ムーコル症治療薬の用途別価格
・北米市場
- 北米のムーコル症治療薬市場規模（種類別、用途別）
- 主要国別のムーコル症治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのムーコル症治療薬市場規模（種類別、用途別）
- 主要国別のムーコル症治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のムーコル症治療薬市場規模（種類別、用途別）
- 主要国別のムーコル症治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のムーコル症治療薬市場規模（種類別、用途別）
- 主要国別のムーコル症治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのムーコル症治療薬市場規模（種類別、用途別）
- 主要国別のムーコル症治療薬市場規模（トルコ、サウジアラビア）
・企業情報
Abbott Laboratories、Biocon、Cadila Pharmaceuticals、Novartis、F. Hoffman La Roche、Merck Sharp and Dohme、Mylan Labs、Bristol Myers Squibb、Bayer、Lonza Group、Sanofi、Johnson and Johnson、Pfizer、Gilead Sciences
・産業チェーン及び販売チャネル分析
- ムーコル症治療薬の産業チェーン分析
- ムーコル症治療薬の原材料
- ムーコル症治療薬の生産プロセス
- ムーコル症治療薬の販売及びマーケティング
- ムーコル症治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- ムーコル症治療薬の産業動向
- ムーコル症治療薬のマーケットドライバー
- ムーコル症治療薬の課題
- ムーコル症治療薬の阻害要因
・主な調査結果

Mucormycosis is a serious infection and needs to be treated with prescription antifungal medicine, usually amphotericin B, posaconazole, or isavuconazole. These medicines are given through a vein (amphotericin B, posaconazole, isavuconazole) or by mouth (posaconazole, isavuconazole).
Market Analysis and Insights: Global Mucormycosis Treatment Drugs Market
Due to the COVID-19 pandemic, the global Mucormycosis Treatment Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Injection accounting for % of the Mucormycosis Treatment Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Mucormycosis Treatment Drugs market size is valued at US$ million in 2021, while the US and Europe Mucormycosis Treatment Drugs are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Mucormycosis Treatment Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Mucormycosis Treatment Drugs include Abbott Laboratories, Biocon, Cadila Pharmaceuticals, Novartis, F. Hoffman La Roche, Merck Sharp and Dohme, Mylan Labs, Bristol Myers Squibb and Bayer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Mucormycosis Treatment Drugs Scope and Segment
Mucormycosis Treatment Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Mucormycosis Treatment Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Injection
Oral
Segment by Application
Hospitals
Clinics
Others
By Company
Abbott Laboratories
Biocon
Cadila Pharmaceuticals
Novartis
F. Hoffman La Roche
Merck Sharp and Dohme
Mylan Labs
Bristol Myers Squibb
Bayer
Lonza Group
Sanofi
Johnson and Johnson
Pfizer
Gilead Sciences
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Mucormycosis Treatment Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Mucormycosis Treatment Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Injection
1.2.3 Oral
1.3 Market by Application
1.3.1 Global Mucormycosis Treatment Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Mucormycosis Treatment Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Mucormycosis Treatment Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Mucormycosis Treatment Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Mucormycosis Treatment Drugs Sales by Region
2.4.1 Global Mucormycosis Treatment Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Mucormycosis Treatment Drugs by Region (2023-2028)
2.5 Global Mucormycosis Treatment Drugs Revenue by Region
2.5.1 Global Mucormycosis Treatment Drugs Revenue by Region (2017-2022)
2.5.2 Global Mucormycosis Treatment Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Mucormycosis Treatment Drugs Sales by Manufacturers
3.1.1 Global Top Mucormycosis Treatment Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Mucormycosis Treatment Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Mucormycosis Treatment Drugs in 2021
3.2 Global Mucormycosis Treatment Drugs Revenue by Manufacturers
3.2.1 Global Mucormycosis Treatment Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Mucormycosis Treatment Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Mucormycosis Treatment Drugs Revenue in 2021
3.3 Global Mucormycosis Treatment Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Mucormycosis Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Mucormycosis Treatment Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Mucormycosis Treatment Drugs Sales by Type
4.1.1 Global Mucormycosis Treatment Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Mucormycosis Treatment Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Mucormycosis Treatment Drugs Sales Market Share by Type (2017-2028)
4.2 Global Mucormycosis Treatment Drugs Revenue by Type
4.2.1 Global Mucormycosis Treatment Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Mucormycosis Treatment Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Mucormycosis Treatment Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Mucormycosis Treatment Drugs Price by Type
4.3.1 Global Mucormycosis Treatment Drugs Price by Type (2017-2022)
4.3.2 Global Mucormycosis Treatment Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Mucormycosis Treatment Drugs Sales by Application
5.1.1 Global Mucormycosis Treatment Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Mucormycosis Treatment Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Mucormycosis Treatment Drugs Sales Market Share by Application (2017-2028)
5.2 Global Mucormycosis Treatment Drugs Revenue by Application
5.2.1 Global Mucormycosis Treatment Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Mucormycosis Treatment Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Mucormycosis Treatment Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Mucormycosis Treatment Drugs Price by Application
5.3.1 Global Mucormycosis Treatment Drugs Price by Application (2017-2022)
5.3.2 Global Mucormycosis Treatment Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Mucormycosis Treatment Drugs Market Size by Type
6.1.1 North America Mucormycosis Treatment Drugs Sales by Type (2017-2028)
6.1.2 North America Mucormycosis Treatment Drugs Revenue by Type (2017-2028)
6.2 North America Mucormycosis Treatment Drugs Market Size by Application
6.2.1 North America Mucormycosis Treatment Drugs Sales by Application (2017-2028)
6.2.2 North America Mucormycosis Treatment Drugs Revenue by Application (2017-2028)
6.3 North America Mucormycosis Treatment Drugs Market Size by Country
6.3.1 North America Mucormycosis Treatment Drugs Sales by Country (2017-2028)
6.3.2 North America Mucormycosis Treatment Drugs Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Mucormycosis Treatment Drugs Market Size by Type
7.1.1 Europe Mucormycosis Treatment Drugs Sales by Type (2017-2028)
7.1.2 Europe Mucormycosis Treatment Drugs Revenue by Type (2017-2028)
7.2 Europe Mucormycosis Treatment Drugs Market Size by Application
7.2.1 Europe Mucormycosis Treatment Drugs Sales by Application (2017-2028)
7.2.2 Europe Mucormycosis Treatment Drugs Revenue by Application (2017-2028)
7.3 Europe Mucormycosis Treatment Drugs Market Size by Country
7.3.1 Europe Mucormycosis Treatment Drugs Sales by Country (2017-2028)
7.3.2 Europe Mucormycosis Treatment Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Mucormycosis Treatment Drugs Market Size by Type
8.1.1 Asia Pacific Mucormycosis Treatment Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Mucormycosis Treatment Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Mucormycosis Treatment Drugs Market Size by Application
8.2.1 Asia Pacific Mucormycosis Treatment Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Mucormycosis Treatment Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Mucormycosis Treatment Drugs Market Size by Region
8.3.1 Asia Pacific Mucormycosis Treatment Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Mucormycosis Treatment Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Mucormycosis Treatment Drugs Market Size by Type
9.1.1 Latin America Mucormycosis Treatment Drugs Sales by Type (2017-2028)
9.1.2 Latin America Mucormycosis Treatment Drugs Revenue by Type (2017-2028)
9.2 Latin America Mucormycosis Treatment Drugs Market Size by Application
9.2.1 Latin America Mucormycosis Treatment Drugs Sales by Application (2017-2028)
9.2.2 Latin America Mucormycosis Treatment Drugs Revenue by Application (2017-2028)
9.3 Latin America Mucormycosis Treatment Drugs Market Size by Country
9.3.1 Latin America Mucormycosis Treatment Drugs Sales by Country (2017-2028)
9.3.2 Latin America Mucormycosis Treatment Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Mucormycosis Treatment Drugs Market Size by Type
10.1.1 Middle East and Africa Mucormycosis Treatment Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Mucormycosis Treatment Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Mucormycosis Treatment Drugs Market Size by Application
10.2.1 Middle East and Africa Mucormycosis Treatment Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Mucormycosis Treatment Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Mucormycosis Treatment Drugs Market Size by Country
10.3.1 Middle East and Africa Mucormycosis Treatment Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Mucormycosis Treatment Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Corporation Information
11.1.2 Abbott Laboratories Overview
11.1.3 Abbott Laboratories Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Abbott Laboratories Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Abbott Laboratories Recent Developments
11.2 Biocon
11.2.1 Biocon Corporation Information
11.2.2 Biocon Overview
11.2.3 Biocon Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Biocon Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Biocon Recent Developments
11.3 Cadila Pharmaceuticals
11.3.1 Cadila Pharmaceuticals Corporation Information
11.3.2 Cadila Pharmaceuticals Overview
11.3.3 Cadila Pharmaceuticals Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Cadila Pharmaceuticals Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Cadila Pharmaceuticals Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Overview
11.4.3 Novartis Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Novartis Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis Recent Developments
11.5 F. Hoffman La Roche
11.5.1 F. Hoffman La Roche Corporation Information
11.5.2 F. Hoffman La Roche Overview
11.5.3 F. Hoffman La Roche Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 F. Hoffman La Roche Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 F. Hoffman La Roche Recent Developments
11.6 Merck Sharp and Dohme
11.6.1 Merck Sharp and Dohme Corporation Information
11.6.2 Merck Sharp and Dohme Overview
11.6.3 Merck Sharp and Dohme Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Merck Sharp and Dohme Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Merck Sharp and Dohme Recent Developments
11.7 Mylan Labs
11.7.1 Mylan Labs Corporation Information
11.7.2 Mylan Labs Overview
11.7.3 Mylan Labs Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Mylan Labs Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Mylan Labs Recent Developments
11.8 Bristol Myers Squibb
11.8.1 Bristol Myers Squibb Corporation Information
11.8.2 Bristol Myers Squibb Overview
11.8.3 Bristol Myers Squibb Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Bristol Myers Squibb Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bristol Myers Squibb Recent Developments
11.9 Bayer
11.9.1 Bayer Corporation Information
11.9.2 Bayer Overview
11.9.3 Bayer Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Bayer Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Bayer Recent Developments
11.10 Lonza Group
11.10.1 Lonza Group Corporation Information
11.10.2 Lonza Group Overview
11.10.3 Lonza Group Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Lonza Group Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Lonza Group Recent Developments
11.11 Sanofi
11.11.1 Sanofi Corporation Information
11.11.2 Sanofi Overview
11.11.3 Sanofi Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Sanofi Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Sanofi Recent Developments
11.12 Johnson and Johnson
11.12.1 Johnson and Johnson Corporation Information
11.12.2 Johnson and Johnson Overview
11.12.3 Johnson and Johnson Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Johnson and Johnson Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Johnson and Johnson Recent Developments
11.13 Pfizer
11.13.1 Pfizer Corporation Information
11.13.2 Pfizer Overview
11.13.3 Pfizer Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Pfizer Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Pfizer Recent Developments
11.14 Gilead Sciences
11.14.1 Gilead Sciences Corporation Information
11.14.2 Gilead Sciences Overview
11.14.3 Gilead Sciences Mucormycosis Treatment Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Gilead Sciences Mucormycosis Treatment Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Gilead Sciences Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Mucormycosis Treatment Drugs Industry Chain Analysis
12.2 Mucormycosis Treatment Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Mucormycosis Treatment Drugs Production Mode & Process
12.4 Mucormycosis Treatment Drugs Sales and Marketing
12.4.1 Mucormycosis Treatment Drugs Sales Channels
12.4.2 Mucormycosis Treatment Drugs Distributors
12.5 Mucormycosis Treatment Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Mucormycosis Treatment Drugs Industry Trends
13.2 Mucormycosis Treatment Drugs Market Drivers
13.3 Mucormycosis Treatment Drugs Market Challenges
13.4 Mucormycosis Treatment Drugs Market Restraints
14 Key Findings in The Global Mucormycosis Treatment Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のムーコル症治療薬市場インサイト及び予測（注射、経口）(Global Mucormycosis Treatment Drugs Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界のムーコル症治療薬市場インサイト及び予測（注射、経口）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp